A randomized trial found that automated insulin delivery improved time in range for adults with diabetes and advanced kidney disease, but long-term benefits remain unknown.
A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
